Trial Profile
Phase II study of nivolumab for advanced non-small-cell lung cancer patients not indicative of cytotoxic chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 24 May 2016 New trial record